Phase II data on Prophage vaccine in GBM published-Agenus
New results from a Phase II study demonstrated that more than 90% of the patients with Glioblastoma multiforme (GBM) treated with Prophage Series G-200 vaccine, from Agenus, were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent GBM patients of three to nine months.
The primary objective of this multi-center, single arm trial was to assess the survival rate at six months. The trial enrolled 41 patients with a mean age of 55 years with surgically resectable recurrent high-grade GBM. The data was published in Neuro-Oncology. See: "Heat-shock protein peptide complex�96 vaccination for recurrent glioblastoma: a phase II, single-arm trial" Orin Bloch et al. Neuro Oncol online December 12, 2013 doi:10.1093/neuonc/not203
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins